Lonza

Lonza, a Pharmaceutical Preparation Manufacturing company headquartered in Switzerland, reported total carbon emissions of about 2.71 billion kg CO2e in 2025. This includes approximately 317 million kg CO2e from Scope 1 emissions, 93 million kg CO2e from Scope 2 (market-based) emissions, and 2.30 billion kg CO2e from Scope 3 emissions.

In 2024, Lonza's total emissions were approximately 2.36 billion kg CO2e, with Scope 1 at about 343 million kg CO2e, Scope 2 (market-based) at about 141 million kg CO2e, and Scope 3 at about 1.88 billion kg CO2e. In 2023, the company's total emissions were approximately 2.46 billion kg CO2e, comprising around 321 million kg CO2e in Scope 1 emissions, 202 million kg CO2e in Scope 2 (market-based) emissions, and 1.94 billion kg CO2e in Scope 3 emissions.

Lonza has set Science Based Targets initiative (SBTi) approved near-term targets to reduce absolute Scope 1 and 2 GHG emissions by 42% by 2030, using a 2021 base year. Additionally, Lonza aims to achieve net-zero emissions by 2050 or earlier. The company is also committed to ensuring that 79% of its suppliers, by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028. Furthermore, Lonza has a target to reduce its GHG emissions intensity (Scope 1 and 2 location-based) by 50% by 2030, compared to a 2018 baseline, per million of sales per year.